Evidence map›Paper›PMID 34903039›Full record

Trial reportCirculation2022

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.

Ahmed M Shaman, Stephen C Bain, George L Bakris, John B Buse, Thomas Idorn, Kenneth W Mahaffey, Johannes F E Mann, Michael A Nauck, Søren Rasmussen, Peter Rossing and 3 more

Open access · hybridFull text readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed, 12 pooled it
21.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 12 syntheses or guidelines pooled it, 229 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 7 countries.

Ahmed M ShamanSydney School of Public Health, University of Sydney, Australia (A.M.S.).
Stephen C BainInstitute of Life Science, Swansea University Medical School, Singleton Hospital, Swansea, United Kingdom (S.C.B.).
George L BakrisUniversity of Chicago Medicine, IL (G.L.B.).ORCID 0000-0003-1183-1267
John B BuseUniversity of North Carolina School of Medicine, Chapel Hill (J.B.B.).ORCID 0000-0002-9723-3876
Thomas IdornNovo Nordisk A/S, Søborg, Denmark (T.I., S.R., B.W.).
Kenneth W MahaffeyStanford Center for Clinical Research (SCCR), Department of Medicine, Stanford School of Medicine, CA (K.W.M.).
Johannes F E MannKfH Kidney Center, Munich, Germany (J.F.E.M.).
Michael A NauckDiabetes Division, Katholisches Klinikum Bochum, St Josef Hospital (Ruhr-Universität Bochum), Bochum, Germany (M.A.N.).
Søren RasmussenNovo Nordisk A/S, Søborg, Denmark (T.I., S.R., B.W.).
Peter RossingSteno Diabetes Center Copenhagen, Gentofte, Denmark (P.R.).
Benjamin WolthersNovo Nordisk A/S, Søborg, Denmark (T.I., S.R., B.W.).
Bernard ZinmanLunenfeld-Tanenbaum Research Institute, Mt Sinai Hospital, University of Toronto, Canada (B.Z.).
Vlado PerkovicThe George Institute for Global Health, The University of New South Wales, Sydney, Australia (A.M.S., V.P.).ORCID 0000-0002-4257-7620
Novo Nordisk (Denmark) · DKFriedrich-Alexander-Universität Erlangen-Nürnberg · DEKatholisches Klinikum Bochum · DELunenfeld-Tanenbaum Research Institute · CASingleton Hospital · GBStanford Medicine · USThe George Institute for Global Health · AUThe University of Sydney · AUUniversity of Chicago · USUniversity of Copenhagen · DKUniversity of North Carolina at Chapel Hill · US

Funding

Pilot & Feasibility ProgramP30DK124723 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$1.6M
NIDDK NIH HHS P30 DK124723
6 · The paper itself

Abstract

backgroundWe assessed the effect of once-weekly semaglutide and once-daily liraglutide on kidney outcomes in type 2 diabetes.

methodsPooled (n=12 637) and by-trial data from SUSTAIN 6 (Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes; n=3297) and LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; n=9340) were assessed for albuminuria change, annual slope of estimated glomerular filtration rate (eGFR) change, and time to persistent eGFR reduction (30%, 40%, 50%, and 57%) from baseline.

resultsThe median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER. In the pooled analysis, semaglutide/liraglutide lowered albuminuria from baseline to 2 years after randomization by 24% versus placebo (95% CI, 20%-27%;

conclusionsIn patients with type 2 diabetes, semaglutide/liraglutide offered kidney-protective effects, which appeared more pronounced in patients with preexisting chronic kidney disease.

Indexed as

AlbuminuriaDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGlomerular Filtration RateGlucagon-Like PeptidesHumansLiraglutideMaleMiddle AgedSemaglutideGlucagon-Like PeptidesLiraglutideSemaglutidealbuminuriachronic kidney diseaseeGFRglucagon-like peptide-1 receptor agonistsliraglutidesemaglutidetype 2 diabetes

Identifiers

PMID34903039
PMCPMC8860212
OpenAlexW4200101053

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.